HEALTH● LOWSep 25 · Sep 25, 2026, 6:38 PM
Genentech's Gazyva gains indication for idiopathic nephrotic syndrome
Seeking Alpha Tech · global
Genentech's drug Gazyva has received a new indication for treating idiopathic nephrotic syndrome. This expands the therapeutic options available for patients with this specific medical condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoLongevity-first healthcare takes spotlight at Abu Dhabi Future Health SummitSouth China Morning PostHEALTH1h agoKenya’s Ebola cases test preparedness beyond NairobiAl Jazeera [en]HEALTH3h agoEven after explosive diarrhea outbreak Trump’s FDA looks to ease food requirementsThe Independent WorldHEALTH5h agoPope Leo recovers after lung surgeryNBC News